Tango

Tango Extend Named "Unified Communications Solution Of The Year" in 2023 Mobile Breakthrough Awards Program

Retrieved on: 
Wednesday, October 25, 2023

LOS ANGELES, Oct. 25, 2023 /PRNewswire-PRWeb/ -- Mobile Breakthrough, a leading independent market intelligence organization that recognizes the top companies, technologies and products in the global wireless and mobile market, today announced that Tango Networks' Tango Extend has been selected as winner of the "Unified Communications Solution of the Year" award in the 7th annual Mobile Breakthrough Awards program.

Key Points: 
  • LOS ANGELES, Oct. 25, 2023 /PRNewswire-PRWeb/ -- Mobile Breakthrough , a leading independent market intelligence organization that recognizes the top companies, technologies and products in the global wireless and mobile market, today announced that Tango Networks ' Tango Extend has been selected as winner of the "Unified Communications Solution of the Year" award in the 7th annual Mobile Breakthrough Awards program.
  • "We're proud to receive the 'Unified Communications Solution Of The Year' award for Extend.
  • The breakthrough Tango Extend solution leverages Microsoft Teams Phone to mobilize fixed-line phone numbers.
  • With Tango Extend, Teams Phone is available very cost-effectively to the deskless workforce, such as frontline, hybrid and gig workers.

Accent Therapeutics Bolsters Leadership Team with Key Executive Hires

Retrieved on: 
Thursday, September 21, 2023

LEXINGTON, Mass., Sept. 21, 2023 /PRNewswire/ -- Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the appointments of Jason Sager, M.D., as Chief Medical Officer, Steven Mennen, Ph.D., as Vice President of Pre-Clinical Development and Stuart Ince, Ph.D. as Vice President of Program Leadership.

Key Points: 
  • "Our dedication to fortifying our team underscores the remarkable progress we've achieved as Accent advances its lead programs towards the clinic," said Shakti Narayan, Chief Executive Officer of Accent.
  • Together, Jason, Steven, and Stuart's combined experience will be immensely valuable as Accent moves towards becoming a clinical-stage company and bringing novel therapies to patients."
  • These key executive hires enhance Accent's positioning to potentially advance two investigational programs into the clinic.
  • Accent is also on track to begin IND-enabling studies for a second undisclosed program by the end of 2023.

Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

Retrieved on: 
Monday, August 28, 2023

TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna’s financial strategy to support the Company’s growth. This appointment underscores the Company's commitment to expanding its operations in Boston and follows the recent appointment of Mr. Brent Meadows as Chief Business Officer.

Key Points: 
  • Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations
    Mr. Caravella’s appointment demonstrates Medicenna’s continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem
    TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO).
  • In this position, Mr. Caravella will lead Medicenna’s financial strategy to support the Company’s growth.
  • This appointment underscores the Company's commitment to expanding its operations in Boston and follows the recent appointment of Mr. Brent Meadows as Chief Business Officer.
  • He brings a wealth of financial leadership experience to Medicenna, having successfully navigated the complex biotech financial landscape and driven growth strategies for prominent life science corporations,” said Fahar Merchant, Ph.D., President and CEO of Medicenna.

Monkton Announces Closed Beta of Monkton Tango, a Serverless SAML 2 Identity Provider

Retrieved on: 
Tuesday, June 13, 2023

TYSONS, Va., June 13, 2023 /PRNewswire-PRWeb/ -- Monkton Inc., is pleased to announce the closed Beta Release of Monkton Tango, a Serverless SAML 2 Identity Provider for Amazon Web Services. Tango deploys into a customer's Amazon Web Services account and allows any trusted organization to enable turnkey CAC/PIV for AWS services like AWS Workspaces, AWS AppStream 2.0—any AWS or other SaaS that supports SAML 2, as well as web applications or website that require CAC/PIV authentication.

Key Points: 
  • Monkton is pleased to announce the closed Beta Release of Monkton Tango, a Serverless SAML 2 Identity Provider for Amazon Web Services.
  • TYSONS, Va., June 13, 2023 /PRNewswire-PRWeb/ -- Monkton Inc. , is pleased to announce the closed Beta Release of Monkton Tango , a Serverless SAML 2 Identity Provider for Amazon Web Services.
  • Continuing, "Monkton Tango provides our customers with an agile means to build Cloud Native solutions and integrate with Software as a Service."
  • Tango deploys into your AWS Organization and auto deploys a Serverless Mutual TLS Portal, enabling you to leverage it as an Identity Provider for CAC and PIV for SAML 2 based services.

Tango launches integration with Crestron’s new Desk Touch desk scheduling hardware

Retrieved on: 
Thursday, May 25, 2023

Crestron launched Desk Touch , an innovative desk scheduling hardware solution with an elegant touch interface, during their Livestream event hosted from Madrid, Spain.

Key Points: 
  • Crestron launched Desk Touch , an innovative desk scheduling hardware solution with an elegant touch interface, during their Livestream event hosted from Madrid, Spain.
  • Tango’s desk booking and conference room scheduling offering, Tango Reserve, seamlessly integrates with Desk Touch, creating an intuitive desk scheduling solution that encourages collaboration, increases desk utilization, and provides enhanced workplace analytics.
  • Crestron is also launching Desk Q for QR-code-based reservations, which Tango will integrate with later in 2023.
  • “Tango has been an instrumental partner in supporting our scheduling portfolio, historically with our room scheduling solutions, and now with our new desk scheduling portfolio.

Tango Named to Inc. Magazine's 2023 Best Workplaces List

Retrieved on: 
Tuesday, May 9, 2023

SAN FRANCISCO, May 9, 2023 /PRNewswire/ -- Tango, the browser extension and desktop application that automatically generates how-to guides while you work, has been named to Inc. Magazine's Best Workplaces of 2023. The list represents a comprehensive measurement of American companies that have excelled in building exceptional workplaces and company culture, whether in-person or remotely.

Key Points: 
  • Tango Ranks Among Highest-Scoring Businesses on Inc. Magazine's Annual List
    SAN FRANCISCO, May 9, 2023 /PRNewswire/ -- Tango , the browser extension and desktop application that automatically generates how-to guides while you work, has been named to Inc. Magazine's Best Workplaces of 2023.
  • The list represents a comprehensive measurement of American companies that have excelled in building exceptional workplaces and company culture, whether in-person or remotely.
  • "We are proud to be recognized by Inc. as a 2023 Best Workplace alongside some of the most dynamic, people-centric companies," said Ken Babcock, Tango's CEO and Co-Founder.
  • Tango, a fully remote company with 40 employees, is one of the honorees selected out of thousands of submissions.

Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Tuesday, May 9, 2023

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2023, and provided business highlights.

Key Points: 
  • We look forward to providing additional data from the trial in 2024,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics.
  • TNG908 proof-of-mechanism as an MTA-cooperative PRMT5 inhibitor demonstrated by marked SDMA reduction in MTAP-deleted cancer cells versus normal tissue.
  • The TNG462 Investigational New Drug (IND) application cleared in January 2023, and the first patient is expected to be dosed in mid-2023.
  • General and administrative expenses were $8.0 million for the three months ended March 31, 2023, compared to $6.8 million for the same period in 2022.

Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

Retrieved on: 
Tuesday, April 18, 2023

BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced highlights from presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.

Key Points: 
  • BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced highlights from presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.
  • “At this year’s AACR Annual Meeting, we presented preclinical data from four programs across our precision oncology portfolio, including two oral presentations.
  • It’s a tremendously exciting time for the field of precision oncology as we and others move into evaluating novel and previously not addressable targets.
  • TNG908 is 15X selective for MTAP-null cancer cells with the potential for broad clinical activity and a large therapeutic index.

NESsT, IKEA Social Entrepreneurship, and Cisco Foundation Welcome New Enterprise Cohort to Refugee Employment Initiative in Poland, Romania

Retrieved on: 
Tuesday, March 21, 2023

NESsT, a global impact investor and venture philanthropist, announced today the first six social enterprises to join the NESsT Refugee Employment Initiative .

Key Points: 
  • NESsT, a global impact investor and venture philanthropist, announced today the first six social enterprises to join the NESsT Refugee Employment Initiative .
  • The Refugee Employment Initiative invests in local businesses committed to creating dignified employment opportunities for refugees living in Central and Eastern Europe to support long-term stability and community development.
  • Close to 4 million refugees from Ukraine have sought refuge in Poland and Romania since the war began.
  • The Being Together Foundation is a social enterprise in Poland specializing in four key business verticals: laundry, catering and bistro, carpentry, and training.

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, March 6, 2023

BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective March 1, 2023, the Compensation Committee of Tango Therapeutics' Board of Directors granted non-qualified stock options to purchase an aggregate of 637,000 shares of its common stock and an aggregate of 106,250 restricted stock units (RSUs) to two new employees under Tango Therapeutics' 2023 Inducement Plan; including 487,500 stock options and 81,250 RSUs to Adam Crystal, M.D., Ph.D. in connection with his acceptance of employment as Tango Therapeutics’ President of Research and Development.

Key Points: 
  • BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective March 1, 2023, the Compensation Committee of Tango Therapeutics' Board of Directors granted non-qualified stock options to purchase an aggregate of 637,000 shares of its common stock and an aggregate of 106,250 restricted stock units (RSUs) to two new employees under Tango Therapeutics' 2023 Inducement Plan; including 487,500 stock options and 81,250 RSUs to Adam Crystal, M.D., Ph.D. in connection with his acceptance of employment as Tango Therapeutics’ President of Research and Development.
  • The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • The options have an exercise price of $5.20 per share, which is equal to the closing price of Tango Therapeutics' common stock on March 1, 2023.
  • The options and RSUs are subject to the terms and conditions of Tango Therapeutics' 2023 Inducement Plan, which was approved in February 2023, and the terms and conditions of the stock option and RSU agreements covering the grant.